1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco...
  2. CORESTA Congress, Kunming, 2018, Agronomy/Phytopathology Groups, APPOST 11

    Field trials with low nicotine tobacco varieties developed by conventional breeding technique: first results

    MALPICA A.(1); EVANS W.(2); ARCHIBALD C.(3); SCOTT L.(4); GARWE D.(5); CHAMANGO A.M.Z.(6); DORLHAC de BORNE F.(7); COLARD S.(8)
    (1) Bergerac Seed and Breeding, Bergerac, France; (2) Imperial Tobacco South Africa Pvt. Ltd, Umhlanga, Durban, South Africa; (3) Alliance One International Services, Camberley, Surrey, U.K.; (4) Universal Leaf Tobacco Co., Richmond, VA, U.S.A.; (5) Tobacco Research Board (TRB), Harare, Zimbabwe; (6) Agricultural Research & Extension Trust (ARET), Lilongwe, Malawi; (7) Imperial Tobacco Limited, Bergerac, France; (8) SEITA - Imperial Brands plc, Paris, France
    In 2015, the World Health Organisation (WHO) Study Group on Tobacco Product Regulation (“TobReg”) issued an advisory note recommending a strategy of reducing nicotine in tobacco to substantially lower levels of 0.4 mg/g. In the U.S., the Food and...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 52

    Biological test procedure for fresh generated cigarette smoke and e-cigarette aerosols under air-liquid interface (ALI) exposure in 24 and 96 multi-well plates

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    Cigarette smoke and e cigarette aerosol contain particulate matter/liquid droplets in the solid phase as well as volatile substances in the gas phase. Both fractions are of potential toxicological relevance and should be considered when assessing...
  4. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 53

    Use of human derived cell lines to increase the biological relevance of cigarette condensate, non-tobacco materials and e-liquids testing

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    The in vitro testing strategy of tobacco products is mainly based on the testing of extracts from cigarette smoke condensates. An accepted industry wide assay battery has been developed over recent years which delivers reliable results for the...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 08

    Indoor air quality and surface deposition assessment following use of an open system e-cigarette

    BAUER N.(1); TSCHIERSKE N.(1); O'CONNELL G.(2); CAHOURS X.(3)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands; (3) SEITA-Imperial Tobacco Limited, Fleury-les-Aubrais, France
    Electronic cigarette (e-cigarette) nicotine delivery devices are growing in popularity worldwide. Both regulators and public health organisations are beginning to examine potential implications that exposure to exhaled e-cigarette aerosol may have on...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “Toxicity Testing in the 21st Century: A Vision and a Strategy”, Fontem Ventures B.V. have investigated the utility of a series of...
  7. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, STPOST 18

    Assessment of the so-called “gateway effect” based on electronic vapour product classifications

    VERRON T.(1); CAHOURS X.(1); CERSON L.(2); COLARD S.(1); O’CONNELL G.(3)
    (1) SEITA-Imperial Tobacco, Fleury-les-Aubrais, France; (2) Imperial Tobacco Limited, Bristol, U.K.; (3) Fontem Ventures B.V., Amsterdam, Netherlands
    Since electronic cigarettes (e-cigs) became popular as alternatives to conventional cigarettes, with subsequent market growth amongst smokers, there is currently a debate as to whether e-cigs may be a "gateway" to conventional cigarette smoking or...
  8. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, STPOST 26

    A review of aerosol exposure systems relative to the analysis of cytotoxicity: a CORESTA In vitro Toxicity Testing Sub-Group perspective

    THORNE D.(1); WIECZOREK R.(2); FUKUSHIMA T.(3); SHIN H.J.(4); LEVERETTE R.(5); BALLANTYNE M.(6); LI X.(7); BOMBICK B.(5)
    (1) British American Tobacco, R&D Centre, Southampton, U.K.; (2) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (3) Japan Tobacco Inc., Scientific Product Assessment Centre, Yokohama, Kanagawa, Japan; (4) KT&G Corporation, Daejeon, South Korea; (5) RAI Services Company, Winston-Salem, NC, U.S.A.; (6) Covance Laboratories Ltd, Harrogate, U.K.; (7) Zhengzhou Tobacco Research Institute of CNTC, Zhengzhou, P.R. China
    Aerosol exposure systems offer researchers a variety of ways to customise the exposure set-up, modify experimental parameters and provide a novel and versatile platform for in vitro aerosol research. These systems produce an aerosol that more closely...
  9. TSRC, Tob. Sci. Res. Conf., 2016, 70, abstr. 23

    Reductions in biomarkers of exposure (BoE) to harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

    O’CONNELL G.(1); GRAFF D.W.(2); D’RUIZ C.(3)
    (1) Fontem Ventures B.V, Amsterdam, The Netherlands; (2) Celerion Inc, Lincoln, NE, USA; (3) Fontem Ventures B.V Greensboro, NC, USA
    Changes in fifteen urine, blood and exhaled breath BoEs of HPHCs representing classes of compounds reported by FDA to be significant contributors to smoking-associated disease risks were measured in 105 clinical-confined subjects following...